Grufity logoGrufity logo

Stryker Corp Stock Research

SYK

275.21USD+2.18(+0.80%)Market Closed

Market Summary

USD275.21+2.18
Market Closed
0.80%

SYK Alerts

SYK Stock Price

SYK RSI Chart

SYK Valuation

Market Cap

104.1B

Price/Earnings (Trailing)

44.16

Price/Sales (Trailing)

5.64

EV/EBITDA

30.28

Price/Free Cashflow

51.15

SYK Price/Sales (Trailing)

SYK Profitability

Operating Margin

62.76%

EBT Margin

14.54%

Return on Equity

14.19%

Return on Assets

6.39%

Free Cashflow Yield

1.96%

SYK Fundamentals

SYK Revenue

Revenue (TTM)

18.4B

Revenue Y/Y

10.66%

Revenue Q/Q

16.14%

SYK Earnings

Earnings (TTM)

2.4B

Earnings Y/Y

-14.95%

Earnings Q/Q

-31%

Price Action

52 Week Range

188.84284.00
(Low)(High)

Last 7 days

2.8%

Last 30 days

2.3%

Last 90 days

11.4%

Trailing 12 Months

8%

SYK Financial Health

Current Ratio

1.63

SYK Investor Care

Dividend Yield

1.01%

Dividend/Share (TTM)

2.78

Shares Dilution (1Y)

0.34%

Diluted EPS (TTM)

6.17

Peers (Alternatives to Stryker)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
SYK
104.1B
18.4B
 2.26% 8.00%
44.16
5.64
 7.84% 18.25%
ISRG
84.2B
6.2B
 -4.47% -13.27%
63.66
13.53
 8.97% -22.43%
BSX
69.1B
12.7B
 0.59% 12.45%
99.06
5.45
 6.68% -32.95%
BDX
67.4B
19.0B
 -5.16% -6.78%
41.86
3.55
 -0.43% -8.78%
EW
49.8B
5.4B
 2.41% -25.12%
32.74
9.26
 2.86% 1.25%
MID-CAP
SWAV
7.2T
489.7M
 9.34% 31.15%
82.2K
16.8K
 106.51% 2464.23%
PEN
10.2B
847.1M
 -3.64% 34.52%
-5.1K
12.05
 13.32% -137.89%
GMED
5.2B
1.0B
 -11.64% -20.31%
30.19
5.09
 6.76% 24.45%
IRTC
3.5B
410.9M
 4.51% -3.13%
-29.82
8.43
 27.29% -14.60%
TNDM
2.7B
801.2M
 1.13% -58.87%
-28.25
3.34
 14.00% -707.69%
SMALL-CAP
SILK
1.7B
138.6M
 -15.68% 29.18%
-30.43
12.07
 36.62% -10.44%
ATEC
1.6B
350.9M
 10.38% 49.06%
-10.84
4.7
 44.26% -5.42%
AVNS
1.3B
820.0M
 -8.35% -12.22%
25.89
1.59
 10.13% 701.59%
CSII
828.4M
239.8M
 0.30% 1.49%
-21.88
3.45
 -4.74% -31.15%

Financials for Stryker

Income Statement (Last 12 Months)
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Revenue2.8%18,44917,94817,62917,43017,108
Gross Profit1.7%11,57811,38711,24711,19310,968
Operating Expenses2.3%8,7378,5418,6358,6218,384
  S&GA Expenses0.1%6,4556,4496,5966,5626,427
  R&D Expenses-0.3%1,4541,4591,4011,3601,235
EBITDA23.9%3,3782,7272,9932,977-
EBITDA Margin18.4%0.18*0.15*0.17*0.17*-
Earnings Before Taxes0.1%2,6832,6792,3582,3002,281
EBT Margin-2.6%0.15*0.15*0.13*0.13*-
Interest Expenses-0.3%324325---
Net Income-4.0%2,3582,4572,0792,0151,994
Net Income Margin-6.6%0.13*0.14*0.12*0.12*-
Free Cahsflow1.0%2,0362,0152,0672,453-
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Assets2.5%36,88435,98336,03236,13734,631
  Current Assets10.3%10,2759,3188,8258,72510,017
    Cash Equivalents29.9%1,8441,4201,0441,4582,944
  Inventory2.9%3,9953,8833,7493,5253,314
  Net PPE6.1%2,9702,7982,8032,7932,833
  Goodwill-0.8%14,88014,99315,11515,22812,918
Liabilities3.8%20,26819,52020,35821,09119,754
  Current Liabilities37.9%6,3034,5714,4044,4084,549
    LT Debt, Non Current-7.0%11,85712,75113,37413,88512,472
Shareholder's Equity0.9%16,61616,46315,67415,04614,877
  Retained Earnings1.9%14,76514,48613,93313,54013,480
  Additional Paid-In Capital0.3%2,0342,0281,9891,9471,890
Accumulated Depreciation3.6%2,8352,7362,7462,7392,665
Shares Outstanding0.0%378378378--
Cashflow (Last 12 Months)
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Cashflow From Operations0.1%2,6242,6212,6653,0143,263
  Share Based Compensation-1.2%168170171174171
Cashflow From Investing4.9%-2,924-3,076-3,395-3,445-859
Cashflow From Financing-26.7%-749-591-396-319-2,365
  Dividend Payments2.5%1,0511,0251,000974950
  Buy Backs-0.00----

Risks for SYK

What is the probability of a big loss on SYK?

35.4%

Probability that Stryker stock will be more than 20% underwater in next one year

18.5%

Probability that Stryker stock will be more than 30% underwater in next one year.

0%

Probability that Stryker stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does SYK drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Stryker was unfortunately bought at previous high price.

Drawdowns

Returns for SYK

Cumulative Returns on SYK

16.7%

10-Year Cumulative Returns

15.9%

7-Year Cumulative Returns

11.4%

5-Year Cumulative Returns

19.6%

3-Year Cumulative Returns

What are the long-term rolling returns for SYK?

FIve years rolling returns for Stryker.

Annualized Returns

Which funds bought or sold SYK recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-03-15
B. Riley Wealth Advisors, Inc.
reduced
-1.48
1,110,670
6,885,670
 0.19%
2023-03-13
Claro Advisors LLC
reduced
-2.24
133,076
791,076
 0.26%
2023-03-10
MATHER GROUP, LLC.
added
26.85
305,164
880,164
 0.02%
2023-03-10
BAILLIE GIFFORD & CO
sold off
-100
-10,000
-
 -%
2023-03-10
VICTORY CAPITAL MANAGEMENT INC
added
10.39
9,627,460
38,583,500
 0.04%
2023-03-08
Capital Asset Advisory Services LLC
added
1.09
54,611
296,611
 0.02%
2023-03-08
SHEETS SMITH WEALTH MANAGEMENT
unchanged
-
128,428
746,428
 0.12%
2023-03-07
Great Lakes Retirement, Inc.
new
-
483,493
483,493
 0.12%
2023-03-06
NORTH STAR ASSET MANAGEMENT INC
added
0.17
4,201,150
24,287,100
 1.51%
2023-03-06
Rockefeller Capital Management L.P.
reduced
-1.36
1,132,000
7,075,000
 0.04%

1–10 of 47

Latest Funds Activity

Are funds buying SYK calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own SYK
No. of Funds

SYK Alerts

Stryker News

MarketBeat

Stryker Co. (NYSE:SYK) Shares Acquired by Harrington Investments ....

MarketBeat,
7 hours ago

Seeking Alpha

Aziyo Biologics: High-Risk/High-Reward (NASDAQ:AZYO).

Seeking Alpha,
8 hours ago

CNBC

Top Wall Street analysts pick these five stocks for the long term.

CNBC,
9 hours ago

MarketWatch

Intuitive Surgical Inc. stock outperforms competitors despite losses on the day.

MarketWatch,
47 hours ago

MarketBeat

American National Bank Sells 547 Shares of Stryker Co. (NYSE:SYK).

MarketBeat,
2 days ago

Nasdaq

Guru Fundamental Report for SYK.

Nasdaq,
2 days ago

Best Stocks

Future Financial Wealth Management LLC makes a $214,000 ....

Best Stocks,
2 days ago

MarketWatch

Zimmer Biomet Holdings Inc. stock rises Thursday, still underperforms market.

MarketWatch,
2 days ago

MarketWatch

Edwards Lifesciences Corp. stock rises Thursday, outperforms market.

MarketWatch,
3 days ago

MarketWatch

Boston Scientific Corp. stock rises Thursday, still underperforms market.

MarketWatch,
3 days ago

MarketWatch

Baxter International Inc. stock rises Thursday, still underperforms market.

MarketWatch,
3 days ago

InvestorPlace

3 Dividend Champions for Long-Term Income.

InvestorPlace,
3 days ago

DirectorsTalk Interviews

Stryker Corporation - Consensus Indicates Potential 4.9% Upside.

DirectorsTalk Interviews,
3 days ago

EIN News

With 5.9% CAGR, Intraoperative Imaging Market Emerging Trends ....

EIN News,
4 days ago

MedTech Dive

Joint replacement business likely to be busy for the next year or ....

MedTech Dive,
5 days ago

MarketWatch

Zimmer Biomet Holdings Inc. stock outperforms competitors on strong trading day.

MarketWatch,
8 days ago

Schedule 13G FIlings of Stryker

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2023
price t rowe associates inc /md/
4.0%
14,929,245
SC 13G/A
Feb 10, 2023
greenleaf trust
5.3%
19,869,434
SC 13G/A
Feb 09, 2023
vanguard group inc
7.99%
30,246,178
SC 13G/A
Feb 01, 2023
blackrock inc.
6.5%
24,494,206
SC 13G/A
Feb 14, 2022
price t rowe associates inc /md/
5.5%
21,156,776
SC 13G/A
Feb 11, 2022
greenleaf trust
5.4%
20,452,972
SC 13G/A
Feb 10, 2022
vanguard group inc
7.60%
28,652,681
SC 13G/A
Feb 07, 2022
blackrock inc.
6.3%
23,860,749
SC 13G/A
Feb 16, 2021
price t rowe associates inc /md/
7.9%
29,889,060
SC 13G/A
Feb 11, 2021
greenleaf trust
5.6%
21,048,539
SC 13G/A

SYK Fair Value

Stryker fair value in different scenarios

The table shows the Fair Value estimates for Stryker for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.
Fair ValueVery PessimisticPessimisticBase CaseOptimisticVery Optimistic
Very Low Inflation

-

-

-

-

-

-

-

-

-

-
Current Inflation

96.21

-65.04%

117.25

-57.40%

147.83

-46.28%

182.93

-33.53%

211.92

-23.00%
Very High Inflation

-

-

-

-

-

-

-

-

-

-

Historical Stryker Fair Value Estimates

Very Pessimistic Case
Pessimistic Case
Fair Value
Optimistic Case
Very Optimistic Case
Closing Stock Price

Recent SEC filings of Stryker

View All Filings
Date Filed Form Type Document
Mar 09, 2023
4
Insider Trading
Mar 09, 2023
4
Insider Trading
Mar 09, 2023
4
Insider Trading
Mar 09, 2023
4
Insider Trading
Mar 09, 2023
4
Insider Trading
Mar 09, 2023
4
Insider Trading
Mar 09, 2023
4
Insider Trading
Mar 09, 2023
4
Insider Trading
Mar 01, 2023
4
Insider Trading
Feb 14, 2023
SC 13G/A
Major Ownership Report

Latest Insider Trading transactions for SYK

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-03-07
Lobo Kevin
acquired
-
-
17,971
chair and ceo
2023-03-07
Fletcher Robert S
acquired
-
-
2,329
vp, chief legal officer
2023-03-07
Becker Yin C
acquired
-
-
790
vp, chief corp affairs officer
2023-03-07
Menon Viju
acquired
-
-
3,162
group president
2023-03-07
Stiles Spencer S
acquired
-
-
3,827
group president
2023-03-07
Boehnlein Glenn S
acquired
-
-
5,325
vp, chief financial officer
2023-03-07
Fink M Kathryn
acquired
-
-
1,664
vp, chief hr officer
2023-03-07
Pierce James Andrew
acquired
-
-
3,827
group president
2023-02-28
Golston Allan C.
sold
-1,437,180
263
-5,459
-
2023-02-28
Golston Allan C.
sold (taxes)
-706,710
262
-2,691
-

1–10 of 50

About Stryker

Kevin A. Lobo
www.stryker.com
46000
Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The MedSurg and Neurotechnology segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. This segment also provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke; and craniomaxillofacial implant products, including cranial, maxillofacial, and chest wall devices, as well as dural substitutes and sealants. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.

SYK Income Statement

2022-09-30
CONSOLIDATED STATEMENTS OF EARNINGS (Unaudited) - USD ($)
shares in Millions, $ in Millions
3 Months Ended9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Income Statement [Abstract]    
Net sales$ 4,479$ 4,160$ 13,247$ 12,407
Cost of sales1,6971,5184,9054,484
Gross profit2,7822,6428,3427,923
Research, development and engineering expenses3643061,128904
Selling, general and administrative expenses1,4551,6024,7044,682
Recall charges(4)161498
Amortization of intangible assets159144469474
Total operating expenses1,9742,0686,3156,158
Operating income8085742,0271,765
Other income (expense), net8(79)(105)(241)
Earnings before income taxes8164951,9221,524
Income taxes057127192
Net earnings$ 816$ 438$ 1,795$ 1,332
Net earnings per share of common stock:    
Basic$ 2.16$ 1.17$ 4.75$ 3.54
Diluted$ 2.14$ 1.14$ 4.70$ 3.48
Weighted-average shares outstanding (in millions):    
Basic378.4377.1378.1376.8
Effect of dilutive employee stock compensation3.45.64.15.5
Diluted381.8382.7382.2382.3
Cash dividends declared per share of common stock (in dollars per share)$ 0.695$ 0.63$ 2.085$ 1.89

SYK Balance Sheet

2022-09-30
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Millions
Sep. 30, 2022
Dec. 31, 2021
Current assets  
Cash and cash equivalents$ 1,420$ 2,944
Marketable securities7775
Accounts receivable, less allowance of $150 ($167 in 2021)3,1033,022
Inventories:  
Materials and supplies852691
Work in process309264
Finished goods2,7222,359
Total inventories3,8833,314
Prepaid expenses and other current assets835662
Total current assets9,31810,017
Property, plant and equipment:  
Land, buildings and improvements1,6651,656
Machinery and equipment3,8693,842
Total property, plant and equipment5,5345,498
Less accumulated depreciation2,7362,665
Property, plant and equipment, net2,7982,833
Goodwill14,99312,918
Other intangibles, net5,0534,840
Noncurrent deferred income tax assets1,3901,760
Other noncurrent assets2,4312,263
Total assets35,98334,631
Current liabilities  
Accounts payable1,2131,129
Accrued compensation9271,092
Income taxes243192
Dividends payable263263
Accrued product liabilities391401
Accrued expenses and other liabilities1,5261,465
Current maturities of debt87
Total current liabilities4,5714,549
Long-term debt, excluding current maturities12,75112,472
Income taxes621913
Other noncurrent liabilities1,5771,820
Total liabilities19,52019,754
Shareholders' equity  
Common stock, $0.10 par value3838
Additional paid-in capital2,0281,890
Retained earnings14,48613,480
Accumulated other comprehensive loss(89)(531)
Total shareholders' equity16,46314,877
Total liabilities and shareholders' equity$ 35,983$ 34,631
Common stock, par value (in dollars per share)$ 0.10$ 0.10